Ácidos graxos ômega 3 e tratamento da esquizofrenia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0101-60832010000500007 http://repositorio.unifesp.br/handle/11600/5579 |
Resumo: | BACKGROUND: Schizophrenia is a complex and debilitating psychiatric disorder, whose primary pharmacological intervention is the use of antipsychotics. There is, however, growing evidence that dietary supplementation with omega 3 fatty acids (n-3) may be beneficial in several psychiatric conditions. OBJECTIVE: To review the efficacy of n-3 as a treatment for schizophrenia. METHODS: Electronic searches of the following databases were performed: Medline, Lilacs e SciELO. The search strategy also included cited reference searching. All relevant randomized controlled trials were included in the review. RESULTS: To date, five out of six randomized, double-blind, and placebo controlled studies obtained improvement in the symptoms of the psychosis. Besides, an advantage in the intake of eicosapentaenoic fatty acid (EPA) in relation to docosahexaenoic fatty acid was designated. Essentially, the intake of 2 g/day of EPA in addition to the standard medication was effective in decreasing the symptoms of schizophrenia. DISCUSSION: The nutritional therapy with EPA revealed to be useful as coadjutant in the treatment of schizophrenia. Therefore, we suggest that the schizophrenic patients should be encouraged to consume balanced and healthy meals rich in EPA and, if the ideal amount is not reached by the diet, the supplementation is likely to be beneficial. |
id |
UFSP_f7210763bd032420f460e03c53488aab |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/5579 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Ácidos graxos ômega 3 e tratamento da esquizofreniaOmega 3 fatty acid and schizophrenia treatmentSchizophrenianutritioneicosapentaeinoic acidomega 3 fatty acidtreatmentEsquizofrenianutriçãoácido eicosapentaenoicoácido graxo ômega 3tratamentoBACKGROUND: Schizophrenia is a complex and debilitating psychiatric disorder, whose primary pharmacological intervention is the use of antipsychotics. There is, however, growing evidence that dietary supplementation with omega 3 fatty acids (n-3) may be beneficial in several psychiatric conditions. OBJECTIVE: To review the efficacy of n-3 as a treatment for schizophrenia. METHODS: Electronic searches of the following databases were performed: Medline, Lilacs e SciELO. The search strategy also included cited reference searching. All relevant randomized controlled trials were included in the review. RESULTS: To date, five out of six randomized, double-blind, and placebo controlled studies obtained improvement in the symptoms of the psychosis. Besides, an advantage in the intake of eicosapentaenoic fatty acid (EPA) in relation to docosahexaenoic fatty acid was designated. Essentially, the intake of 2 g/day of EPA in addition to the standard medication was effective in decreasing the symptoms of schizophrenia. DISCUSSION: The nutritional therapy with EPA revealed to be useful as coadjutant in the treatment of schizophrenia. Therefore, we suggest that the schizophrenic patients should be encouraged to consume balanced and healthy meals rich in EPA and, if the ideal amount is not reached by the diet, the supplementation is likely to be beneficial.CONTEXTO: A esquizofrenia é uma desordem psiquiátrica complexa e debilitante cujo tratamento de base é realizado com medicamentos antipsicóticos. No entanto, evidências sugerem que a suplementação dietética com ácidos graxos ômega 3 (n-3) pode ser benéfica em diversas desordens psiquiátricas. OBJETIVO: Revisar a eficácia do n-3 como coadjuvante no tratamento farmacológico da esquizofrenia. MÉTODOS: Realizou-se uma pesquisa nas bases de dados eletrônicas Medline, Lilacs e SciELO. A estratégia de busca também incluiu a busca em árvore. Todos os estudos randomizados e controlados relevantes foram incluídos nesta revisão, independentemente do ano de publicação. RESULTADOS: Até o momento, foram divulgados seis estudos randomizados, duplo-cegos placebo controlados; cinco deles apresentaram resultados positivos na melhora dos sintomas da esquizofrenia, assinalando, ainda, superioridade do ácido graxo eicosapentaenoico (EPA) em relação ao ácido graxo docosaexaenoico. Em geral, o consumo de 2 g/dia de EPA conjuntamente com a medicação antipsicótica usual parece reduzir a sintomatologia da esquizofrenia, particularmente os sintomas positivos. CONCLUSÃO: A terapia nutricional com EPA mostrou-se útil como coadjuvante no tratamento da esquizofrenia. Por conseguinte, sugere-se que os pacientes esquizofrênicos sejam encorajados a consumir refeições balanceadas e saudáveis ricas em EPA e, caso a quantidade ideal não seja atingida pela dieta, a suplementação pode ser benéfica.Universidade Federal de São Paulo (UNIFESP) Programa de Pós-Graduação em NutriçãoCentro Universitário São CamiloUNIFESP, Programa de Pós-Graduação em NutriçãoSciELOConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Faculdade de Medicina da Universidade de São PauloUniversidade Federal de São Paulo (UNIFESP)Centro Universitário São CamiloZemdegs, Juliane Costa Silva [UNIFESP]Pimentel, Gustavo Duarte [UNIFESP]Priel, Margareth Rose2015-06-14T13:41:31Z2015-06-14T13:41:31Z2010-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion223-227application/pdfhttp://dx.doi.org/10.1590/S0101-60832010000500007Archives of Clinical Psychiatry. Faculdade de Medicina da Universidade de São Paulo, v. 37, n. 5, p. 223-227, 2010.10.1590/S0101-60832010000500007S0101-60832010000500007.pdf0101-6083S0101-60832010000500007http://repositorio.unifesp.br/handle/11600/5579WOS:000283337900007porArchives of Clinical Psychiatryinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-04T23:49:36Zoai:repositorio.unifesp.br/:11600/5579Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-04T23:49:36Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Ácidos graxos ômega 3 e tratamento da esquizofrenia Omega 3 fatty acid and schizophrenia treatment |
title |
Ácidos graxos ômega 3 e tratamento da esquizofrenia |
spellingShingle |
Ácidos graxos ômega 3 e tratamento da esquizofrenia Zemdegs, Juliane Costa Silva [UNIFESP] Schizophrenia nutrition eicosapentaeinoic acid omega 3 fatty acid treatment Esquizofrenia nutrição ácido eicosapentaenoico ácido graxo ômega 3 tratamento |
title_short |
Ácidos graxos ômega 3 e tratamento da esquizofrenia |
title_full |
Ácidos graxos ômega 3 e tratamento da esquizofrenia |
title_fullStr |
Ácidos graxos ômega 3 e tratamento da esquizofrenia |
title_full_unstemmed |
Ácidos graxos ômega 3 e tratamento da esquizofrenia |
title_sort |
Ácidos graxos ômega 3 e tratamento da esquizofrenia |
author |
Zemdegs, Juliane Costa Silva [UNIFESP] |
author_facet |
Zemdegs, Juliane Costa Silva [UNIFESP] Pimentel, Gustavo Duarte [UNIFESP] Priel, Margareth Rose |
author_role |
author |
author2 |
Pimentel, Gustavo Duarte [UNIFESP] Priel, Margareth Rose |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) Centro Universitário São Camilo |
dc.contributor.author.fl_str_mv |
Zemdegs, Juliane Costa Silva [UNIFESP] Pimentel, Gustavo Duarte [UNIFESP] Priel, Margareth Rose |
dc.subject.por.fl_str_mv |
Schizophrenia nutrition eicosapentaeinoic acid omega 3 fatty acid treatment Esquizofrenia nutrição ácido eicosapentaenoico ácido graxo ômega 3 tratamento |
topic |
Schizophrenia nutrition eicosapentaeinoic acid omega 3 fatty acid treatment Esquizofrenia nutrição ácido eicosapentaenoico ácido graxo ômega 3 tratamento |
description |
BACKGROUND: Schizophrenia is a complex and debilitating psychiatric disorder, whose primary pharmacological intervention is the use of antipsychotics. There is, however, growing evidence that dietary supplementation with omega 3 fatty acids (n-3) may be beneficial in several psychiatric conditions. OBJECTIVE: To review the efficacy of n-3 as a treatment for schizophrenia. METHODS: Electronic searches of the following databases were performed: Medline, Lilacs e SciELO. The search strategy also included cited reference searching. All relevant randomized controlled trials were included in the review. RESULTS: To date, five out of six randomized, double-blind, and placebo controlled studies obtained improvement in the symptoms of the psychosis. Besides, an advantage in the intake of eicosapentaenoic fatty acid (EPA) in relation to docosahexaenoic fatty acid was designated. Essentially, the intake of 2 g/day of EPA in addition to the standard medication was effective in decreasing the symptoms of schizophrenia. DISCUSSION: The nutritional therapy with EPA revealed to be useful as coadjutant in the treatment of schizophrenia. Therefore, we suggest that the schizophrenic patients should be encouraged to consume balanced and healthy meals rich in EPA and, if the ideal amount is not reached by the diet, the supplementation is likely to be beneficial. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-01-01 2015-06-14T13:41:31Z 2015-06-14T13:41:31Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0101-60832010000500007 Archives of Clinical Psychiatry. Faculdade de Medicina da Universidade de São Paulo, v. 37, n. 5, p. 223-227, 2010. 10.1590/S0101-60832010000500007 S0101-60832010000500007.pdf 0101-6083 S0101-60832010000500007 http://repositorio.unifesp.br/handle/11600/5579 WOS:000283337900007 |
url |
http://dx.doi.org/10.1590/S0101-60832010000500007 http://repositorio.unifesp.br/handle/11600/5579 |
identifier_str_mv |
Archives of Clinical Psychiatry. Faculdade de Medicina da Universidade de São Paulo, v. 37, n. 5, p. 223-227, 2010. 10.1590/S0101-60832010000500007 S0101-60832010000500007.pdf 0101-6083 S0101-60832010000500007 WOS:000283337900007 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Archives of Clinical Psychiatry |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
223-227 application/pdf |
dc.publisher.none.fl_str_mv |
Faculdade de Medicina da Universidade de São Paulo |
publisher.none.fl_str_mv |
Faculdade de Medicina da Universidade de São Paulo |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268408999444480 |